Human serum albumin (HSA) is a monomeric allosteric protein. Here, the effect of ibuprofen on denitrosylation kinetics (k off ) and spectroscopic properties of HSA-heme-Fe(II)-NO is reported. The k off value increases from (1.4 ± 0.2) Â 10 À4 s
Human serum albumin (HSA), the most abundant protein in plasma, is characterized by an extraordinary ligand binding capacity, providing a depot and carrier for many compounds. Moreover, HSA affects pharmacokinetics of many drugs, holds some ligands in a strained orientation, providing their metabolic modification, renders potential toxins harmless transporting them to disposal sites, accounts for most of the antioxidant capacity of human serum, and displays (pseudo-)enzymatic properties [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
HSA displays a modular structure containing three homologous domains (named I, II, and III). Each domain consists of two separate helical sub-domains (named A and B) connected by random coils. Terminal regions of sequential domains contribute to the formation of interdomain helices linking domain IB to IIA, and IIB to IIIA (Fig. 1) [2, 3, 6, 8, 12, 14, 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] .
The structural organization of HSA provides a variety of ligand binding sites (Fig. 1) . In particular, heme binds to the D-shaped fatty acid site 1 (FA1) located within the IB subdomain, contacting the IB-IIA polypeptide linker and the long IB-IIA transdomain helix. The heme binding cavity is limited by Tyr138 and Tyr161 that provide p-p stacking interaction with the porphyrin and supply a donor oxygen (from Tyr161) coordinating the heme iron [23, 25] . Moreover, His146 was suggested as the putative ligand able to coordinate to the heme iron in the sixth position upon drug binding to Sudlow's sites I and II [26] [27] [28] [29] [30] .
Bulky heterocyclic molecules (e.g., warfarin) bind preferentially to Sudlow's site I, whereas Sudlow's site II is preferred by aromatic carboxylates with an extended conformation (e.g., ibuprofen) [1] [2] [3] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 26, [31] [32] [33] [34] [35] [36] .
The heme pocket and Sudlow's site I are allosterically-coupled. Indeed, Sudlow's site I ligands affect thermodynamics and/or kinetics of heme binding to HSA and vice versa, thus affecting the heme-Fe-atom spectroscopic properties and reactivity [10] [11] [12] [13] [14] [26] [27] [28] 30, [37] [38] [39] [40] [41] [42] . Similarly, the secondary ibuprofen binding site (FA6) has been suggested to be allosterically-coupled with the heme site [30, 40, 42] . Eventually, the FA2 site has been described to account for the positive modulation of affinity of the heme for the FA1 binding site, FA2 being the modulator site that controls fatty acid-induced conformational switch [38, 40] .
Here, the effect of ibuprofen on denitrosylation kinetics and absorbance spectroscopic properties of HSA-heme-Fe(II)-NO is reported. It is important to outline that HSA-heme-Fe(II)-NO displays a severe weakening of the proximal heme-Fe-atom bond, which is restored upon binding of heterotropic ligands, such as bezafibrate, clofibrate, ibuprofen and warfarin [26, 27, 30] . Ibuprofen modulates NO dissociation kinetics and affects the absorbance spectroscopic properties of HSA-heme-Fe(II)-NO by binding to three distinct sites (i.e., Sudlow's site II, formed by the FA3 and FA4 sites, the FA6 region, and the FA2 pocket). This highlights the allosteric modulation of HSA-heme-Fe(II) reactivity by heterotropic effectors which appears to be linked to the coordination state of the HSA-hemeFe(II)-atom.
Materials and methods
HSA (P96%, essentially fatty acid free), hemin (protoporphyrin IX-Fe(III)) chloride, and ibuprofen were obtained from Sigma-Aldrich (St. Louis, MO, USA). NO (from Aldrich Chemical Co., Milwaukee, WI, USA) was purified by flowing it through an NaOH column in order to remove acidic nitrogen oxides. CO was purchased from Linde AG (Höllriegelskreuth, Germany).
HSA-heme-Fe(II) (=5. The time course for HSA-heme-Fe(II)-NO denitrosylation was fitted to a single-exponential process according to the minimum reaction mechanism represented by Scheme 1 [41, 44] .
Values of k off have been determined from data analysis according to Eq. (1) [45] :
½HSA-heme-FeðIIÞ-NO t ¼ ½HSA-heme-FeðIIÞ-NO i Â e 
where k off 1 , k off 2 , and k off 3 indicate values of k off occurring at Y ¼ ½ibuprofen=ðH þ ½ibuprofenÞ ð3Þ
Results and discussion
Under all the experimental conditions, the time course for NO dissociation from HSA-heme-Fe(II)-NO conforms to a single-exponential decay for more than 90% of its course, in the absence and presence of ibuprofen (Fig. 1) . Values of the first-order rate constant for NO dissociation from HSA-heme-Fe(II)-NO (i.e., k off ) are wavelength-and [CO]-independent in the presence of dithionite excess (data not shown).
Values of k off for HSA-heme-Fe(II)-NO denitrosylation increase from (1.4 ± 0.2) Â 10 À4 s
À1
, in the absence of ibuprofen (i.e., k off + in Eq. (2)), to (9.5 ± 1.2) Â 10 À3 s À1 , in the presence of 1.0 Â 10 À2 M ibuprofen ( Fig. 1 and Table 1 ). The k off + value here reported (=(1.4 ± 0.2) Â 10 À4 s
, at pH 7.0 and 10.0°C) is closely similar to that previously obtained (=(1.3 ± 0.2) Â 10 À4 s
, at pH 7.0 and 20.0°C) [41] . The analysis of the dependence of k off on the ibuprofen concentration (Fig. 1) , according to Eq. (2), allowed to determine the values of the dissociation equilibrium constants for drug binding to HSA-heme-Fe(II)-NO (i.e., K 1 = (3.1 ± 0.4) Â 10 À7 M, K 2 = (1.7 ± 0.2) Â 10 À4 M, and K 3 = (2.2 ± 0.2) Â 10 À3 M) (Fig. 1) .
Mixing of the HSA-heme-Fe(II)-NO and ibuprofen solutions causes a shift of the optical absorption maximum of the Soret band (i.e., k max ) from 389 nm (i.e., HSA-heme-Fe(II)-NO) to 418 nm (i.e., ibuprofen-HSA-heme-Fe(II)-NO) and a change of the extinction reported in the literature [29] and they indeed correspond to those obtained for ferrous nitrosylated penta-coordinated heme-proteins [46] . Absorbance changes of HSA-heme-Fe(II)-NO on the ibuprofen concentration follow a single equilibrium; the analysis of data according to Eq. (3) (Fig. 1) allowed to determine the value of the dissociation equilibrium constant for drug binding to HSAheme-Fe(II)-NO (i.e., H = (2.6 ± 0.3) Â 10 À3 M). The value of the dissociation equilibrium constant for ibuprofen binding to HSAheme-Fe(II)-NO obtained by absorbance spectroscopy (i.e., H) is in excellent agreement with that of K 3 determined from drug-dependent kinetics of HSA-heme-Fe(II)-NO denitrosylation (see Fig. 1 ). Data reported in Fig. 1 indicate that ibuprofen binds to three independent sites of HSA-heme-Fe(II)-NO modulating allosterically NO dissociation kinetics. However, only one binding site is spectroscopically-linked to the chromofore (i.e., the heme-Fe(II)-NO atom).
Values of K 1 (=3.1 Â 10 À7 M) and K 2 (=1.7 Â 10 À4 M) for ibuprofen binding to HSA-heme-Fe(II)-NO (present study) are higher than those reported for drug binding to HSA-heme-Fe(III) (K 1 = 8.0 Â 10 À8 M and K 2 = 5.0 Â 10 À5 M) [26, 30, 42] , and are comparable to those reported for drug binding to heme-free HSA (K 1 = 3.7 Â 10 À7 M and K 2 = 4.0 Â 10 À5 M) [3, 26, 42, 47] . These findings indicate that the redox and the (un)ligated state of the heme-Fe-atom affects allosterically ibuprofen binding to HSAheme-Fe. Moreover, only one ibuprofen binding site (characterized by K 2 ) appears to be allosterically-linked to the heme cleft (i.e., FA1).
The analysis of data shown in Fig. 1 , according to Eqs. (2) and (3), indicates that ibuprofen binds to three independent sites of HSA-heme-Fe(II)-NO, the value of the third site constant K 3 (=H) is 2.2 Â 10 À3 M). Ibuprofen primary binding to Sudlow's site II, formed by the FA3 and FA4 sites, and secondary binding to the FA6 region have been substantiated by X-ray crystallography [13] . In order to account for a third, low affinity ibuprofen binding site the modulatory FA2 site may be envisaged. Indeed, the FA2 site acts as the modulatory site that controls fatty acid-induced conformational switch and therefore may account for heme stabilization within the FA1 binding site [38, 40] . Actually, preliminary results indicate a positive modulation of heme binding by high (>1.0 mM) ibuprofen concentration that in turn could explain the observed hexa-coordination of HSA-heme-Fe(III) at similar ibuprofen concentration [30] . Ibuprofen binding to FA2 reflects indeed the stabilization of the six-coordinate derivative of the HSA-heme-Fe(II)-NO species, which is instead predominantly five-coordinated in the absence of allosteric effectors that increase heme affinity. Actually, ligand binding to FA2 should affect the Phe149-Tyr150 dyad with a more favorable orientation of Phe149 with respect to the Fe(III)heme moiety (see [26] [27] [28] 30, 40, 48] ).
The increase of k off for NO dissociation from HSA-heme-Fe(II)-NO upon stabilization of the six-coordinated heme-Fe(II)-NO-atom is reminiscent with what reported for warfarin-induced six-coordination of HSA-heme-Fe(II)-NO [41] , and for 1-methyl-imidazole-(1-MeIm-) mediated six-coordination of the heme-Fe(II)-NO model compound [43] (Table 1) , clearly indicating that (unlike for the heme-Fe-atom ligand CO [49] ) penta-coordinated heme-Fe(II)-NO is characterized by a slower NO dissociation rate than the hexacoordinated species.
Furthermore, values of k off for NO dissociation from ferrous nitrosylated heme-proteins may also reflect structurally-different stabilization mode(s) of the heme-Fe(II)-bound NO by heme distal residue(s). In fact, the stabilization of the heme-bound ligand is achieved by hydrogen bonding to the heme distal His residue in human Hb [50] . In contrast, Arg145 may stabilize the HSA-hemeFe(II)NO complex by hydrogen bonding [41] . As a whole, present data reinforce the idea that HSA could be taken as the prototype of monomeric allosteric proteins. Furthermore, HSA-heme represents a unique case within heme-proteins since allosteric effectors modulate both heme binding to HSA and the heme-Fe-atom reactivity.
